The only assay designed for critical treatment decisions in clinically low- and intermediate-risk prostate cancer patients. See how the Oncotype DX GPS test compares to other genomic tests:
Comparison of prostate biopsy genomic tests
|
Oncotype DX GPS assay |
Prolaris® Test |
Decipher® Prostate Biopsy Test |
Genes selected based on their performance in prostate cancer in the biopsy setting1-4 |
 |
|
|
Extensive clinical validation across large cohorts of GS 3+3 and 3+4 patients who are eligible for active surveillance1,4-20 |
 |
|
|
Optimized and analytically validated for small prostate biopsy tissue samples2,10,19 |
 5 ng of RNA |
200 ng of RNA |
25-100 ng of RNA |
Validated endpoints in a biopsy setting:
Oncotype DX GPS assay |
Prolaris® Test |
Decipher® Prostate Biopsy Test |
Metastasis after RP13
PCM after RP13
AP (Gleason grade ≥ 4+3 and/or pT3+)13*
BCR7,13
|
Metastasis after RP20
PCM after conservative management (watchful waiting)15,16
BCR20
|
Metastasis after RP3
PCM after RP3
AP (Gleason ≥ 4+3 and pT3b+ only)17*
|
RP = radical prostatectomy; BCR = biochemical recurrence; PCM = prostate cancer mortality
*Prospective validation data for this clinical endpoint.21
|